Gossamer Bio, Inc. (GOSS) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 60.43M USD. 52-week range 9.12 to 309.60 USD. Data as of 2026-10-09.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to ...